加拿大終止與康希諾生物(06185.HK)新冠疫苗合作項目
加拿大國家研究委員會(NRC)表示,已經結束與康希諾生物(06185.HK)在研發新冠病毒疫苗的合作,因康希諾生物遲遲未取得運送疫苗的許可證。
康希諾生物5月同意將研發中的疫苗運往加拿大,與NRC合作進行疫苗測試。NRC發表聲明稱,由於康希諾生物目前並未獲得授權運送疫苗,NRC的團隊及研發設施將與其他公司進行合作。
康希諾生物行政總裁宇學峰較早時接受訪問時表示,中國當局遲遲未能決定是否批准將疫苗運送到加拿大,一些政府部門不清楚疫苗是否應該進行全球測試又或者是如何進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.